Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Seres trial news 'disappointing,' but an isolated story, says JMP » 15:23
07/22/21
07/22
15:23
07/22/21
15:23
MCRB

Seres Therapeutics

$8.72 /

-12.075 (-58.07%)

, EVLO

Evelo Biosciences

$10.10 /

-2.77 (-21.52%)

, KLDO

Kaleido Biosciences

$6.09 /

-1.15 (-15.88%)

JMP Securities analyst…

JMP Securities analyst Gobind Singh reiterated a Market Perform rating on Seres Therapeutics (MCRB) after the company reported that the Phase 2 ECO-RESET trial did not meet its primary endpoint of clinical remission at week 10. Singh said that while the news is "disappointing" and "an obvious setback" for SER-287, he views the result as an isolated story with a specific microbiome-based therapeutic that does not have any read-through to other MBT companies, including Evelo Biosciences (EVLO) and Kaleido Biosciences (KLDO). In addition, Singh noted he would be a buyer on both Evelo and Kaleido, both Outperform-rated, as the recent selloff is unwarranted, making the risk/reward even more attractive.

ShowHide Related Items >><<
MCRB Seres Therapeutics
$8.72 /

-12.075 (-58.07%)

KLDO Kaleido Biosciences
$6.09 /

-1.15 (-15.88%)

EVLO Evelo Biosciences
$10.10 /

-2.77 (-21.52%)

MCRB Seres Therapeutics
$8.72 /

-12.075 (-58.07%)

07/22/21 Piper Sandler
Piper trims Seres Therapeutics price target to $32, would buy on weakness
07/22/21 Cowen
Seres Therapeutics' Phase IIb study fails to demonstrate efficacy, says Cowen
07/09/21 Chardan
Seres Therapeutics assumed with a Buy at Chardan
07/02/21 Canaccord
Seres Therapeutics deal with Nestle validates high interest, says Canaccord
EVLO Evelo Biosciences
$10.10 /

-2.77 (-21.52%)

07/09/21 Chardan
Evelo Biosciences assumed with a Neutral at Chardan
06/23/21 JMP Securities
JMP raises Evelo Biosciences price target to $38 after Rapt reports data
06/23/21 Cantor Fitzgerald
Evelo Biosciences initiated with an Overweight at Cantor Fitzgerald
06/23/21 Cantor Fitzgerald
Evelo Biosciences initiated with an Overweight at Cantor Fitzgerald
KLDO Kaleido Biosciences
$6.09 /

-1.15 (-15.88%)

07/09/21 Chardan
Kaleido Biosciences assumed with a Buy at Chardan
02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
MCRB Seres Therapeutics
$8.72 /

-12.075 (-58.07%)

KLDO Kaleido Biosciences
$6.09 /

-1.15 (-15.88%)

EVLO Evelo Biosciences
$10.10 /

-2.77 (-21.52%)

  • 04
    Feb
  • 29
    Jan
  • 13
    Aug
MCRB Seres Therapeutics
$8.72 /

-12.075 (-58.07%)

KLDO Kaleido Biosciences
$6.09 /

-1.15 (-15.88%)

EVLO Evelo Biosciences
$10.10 /

-2.77 (-21.52%)

Initiation
Kaleido Biosciences assumed with a Buy at Chardan » 16:29
07/09/21
07/09
16:29
07/09/21
16:29
KLDO

Kaleido Biosciences

$7.96 /

-0.02 (-0.25%)

Chardan analyst Keay…

Chardan analyst Keay Nakae assumed coverage of Kaleido Biosciences with a Buy rating and $15 price target. The firm's prior rating and price target remain unchanged.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$7.96 /

-0.02 (-0.25%)

KLDO Kaleido Biosciences
$7.96 /

-0.02 (-0.25%)

02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
KLDO Kaleido Biosciences
$7.96 /

-0.02 (-0.25%)

  • 04
    Feb
KLDO Kaleido Biosciences
$7.96 /

-0.02 (-0.25%)

Over a month ago
Hot Stocks
Kaleido Biosciences reaffirms cash runway into Q1 of 2022 » 07:35
05/04/21
05/04
07:35
05/04/21
07:35
KLDO

Kaleido Biosciences

/

+

As of March 31, 2021, the…

As of March 31, 2021, the company reported cash and cash equivalents of $92.4M. The company continues to manage its operating expenses and, as a result, has cash runway into the first quarter of 2022.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
/

+

KLDO Kaleido Biosciences
/

+

02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
KLDO Kaleido Biosciences
/

+

  • 04
    Feb
  • 02
    Jun
KLDO Kaleido Biosciences
/

+

Earnings
Kaleido Biosciences reports Q1 EPS (58c), consensus (59c) » 07:35
05/04/21
05/04
07:35
05/04/21
07:35
KLDO

Kaleido Biosciences

/

+

Reports Q1 collaboration…

Reports Q1 collaboration revenue $297,000. "Kaleido is off to a strong start in 2021 marked by positive results from our 350-patient clinical study with KB109 in outpatients with mild-to-moderate COVID-19 and a recently completed financing, which will support the continued expansion of our novel, targeted Microbiome Metabolic Therapy candidates," said Dan Menichella, President and CEO of Kaleido. "Consistent with the interim findings we reported earlier this year, results from the full dataset demonstrated that KB109 has a favorable safety and tolerability profile and reduced COVID-19 related healthcare utilization and recovery time in patients with one or more comorbidity. Based on these results, we are investing in the manufacturing of KB109 and are initiating an IND application with the FDA."

ShowHide Related Items >><<
KLDO Kaleido Biosciences
/

+

KLDO Kaleido Biosciences
/

+

02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
KLDO Kaleido Biosciences
/

+

  • 04
    Feb
  • 02
    Jun
KLDO Kaleido Biosciences
/

+

Over a quarter ago
Conference/Events
Jefferies to hold a virtual summit » 09:16
04/22/21
04/22
09:16
04/22/21
09:16
EVLO

Evelo Biosciences

$11.93 /

+1.06 (+9.75%)

, KLDO

Kaleido Biosciences

$6.07 /

-0.02 (-0.33%)

, MCRB

Seres Therapeutics

$20.40 /

+0.76 (+3.87%)

, PHGE

BiomX

$6.50 /

+0.25 (+4.00%)

, SYRX

Sysorex

/

+

Microbiome-Based…

Microbiome-Based Therapeutics Virtual Summit will be held on April 22.

ShowHide Related Items >><<
PHGE BiomX
$6.50 /

+0.25 (+4.00%)

MCRB Seres Therapeutics
$20.40 /

+0.76 (+3.87%)

KLDO Kaleido Biosciences
$6.07 /

-0.02 (-0.33%)

EVLO Evelo Biosciences
$11.93 /

+1.06 (+9.75%)

EVLO Evelo Biosciences
$11.93 /

+1.06 (+9.75%)

04/12/21 Jefferies
Jefferies upgrades Evelo Biosciences to Buy on increased microbiome momentum
04/12/21 Jefferies
Evelo Biosciences upgraded to Buy from Hold at Jefferies
03/12/21 Chardan
Evelo Biosciences price target raised to $15 from $10 at Chardan
01/25/21 JMP Securities
Evelo Biosciences price target raised to $36 from $27 at JMP Securities
KLDO Kaleido Biosciences
$6.07 /

-0.02 (-0.33%)

02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
MCRB Seres Therapeutics
$20.40 /

+0.76 (+3.87%)

04/13/21 Evercore ISI
Finch Therapeutics initiated with an Outperform at Evercore ISI
04/13/21 Jefferies
Finch Therapeutics initiated with a Buy at Jefferies
03/05/21 Chardan
Seres Therapeutics upgraded to Buy from Neutral at Chardan
01/12/21 Piper Sandler
Additional Seres '109 analysis strengthens BLA filing, says Piper Sandler
PHGE BiomX
$6.50 /

+0.25 (+4.00%)

04/15/21 Ladenburg
Ladenburg starts BiomX with $25 target, says buy ahead of acne data
04/15/21 Ladenburg
BiomX initiated with a Buy at Ladenburg
02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
SYRX Sysorex
/

+

MCRB Seres Therapeutics
$20.40 /

+0.76 (+3.87%)

KLDO Kaleido Biosciences
$6.07 /

-0.02 (-0.33%)

EVLO Evelo Biosciences
$11.93 /

+1.06 (+9.75%)

  • 04
    Feb
  • 29
    Jan
  • 13
    Aug
  • 25
    Jun
  • 02
    Jun
KLDO Kaleido Biosciences
$6.07 /

-0.02 (-0.33%)

EVLO Evelo Biosciences
$11.93 /

+1.06 (+9.75%)

Hot Stocks
Kaleido Biosciences announces collaboration with Jenq to explore MMTs » 07:35
04/20/21
04/20
07:35
04/20/21
07:35
KLDO

Kaleido Biosciences

$6.17 /

-0.31 (-4.78%)

Kaleido Biosciences…

Kaleido Biosciences announced a research collaboration with researcher Robert Jenq, M.D. Professor of Genomic Medicine, at The University of Texas MD Anderson Cancer Center, to explore the potential of Kaleido's novel Microbiome Metabolic Therapies, or MMT, in preventing febrile neutropenia-a serious complication associated with hematopoietic stem cell transplantations, or HSCT. Within the collaboration, selected MMTs will be evaluated in disease animal models developed by Dr. Jenq, to further explore the molecular mechanisms by which MMTs act on the microbiome and gut barrier function and support the identification of a lead compound from Kaleido's compound library.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$6.17 /

-0.31 (-4.78%)

KLDO Kaleido Biosciences
$6.17 /

-0.31 (-4.78%)

02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
KLDO Kaleido Biosciences
$6.17 /

-0.31 (-4.78%)

  • 04
    Feb
  • 02
    Jun
KLDO Kaleido Biosciences
$6.17 /

-0.31 (-4.78%)

Hot Stocks
Kaleido Biosciences reports results from non-IND study of KB109 » 07:06
03/24/21
03/24
07:06
03/24/21
07:06
KLDO

Kaleido Biosciences

$9.95 /

-0.96 (-8.80%)

Kaleido Biosciences…

Kaleido Biosciences reported results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19. An analysis from the full dataset demonstrated a reduction in overall COVID-19 related healthcare utilization-comprised of hospitalizations, emergency room visits, and urgent care visits. The study also demonstrated a significant reduction in recovery time for patients age 45 and older or with one or more comorbidity who received KB109 plus self-supportive care as compared to patients receiving self-supportive care alone. The study was a multi-center, open label, controlled clinical study of 350 patients in which 181 received KB109 plus self-supportive care and 169 received self-supportive care alone. KB109 is a novel, orally administered product candidate based on the Company's Microbiome Metabolic Therapy platform. Summary of Results: Primary Endpoint: KB109 demonstrated an overall favorable safety and tolerability profile with no unexpected treatment-related adverse events. KB109 reduced healthcare utilization, as measured by the total number of hospitalizations, emergency room visits, and urgent care visits by approximately 62 percent among patients with one or more comorbidity and by approximately 51 percent overall. KB109 showed the greatest impact for patients with one or more underlying comorbidity, who have a considerably longer disease course. For patients with one or more comorbidity, KB109 reduced median time to resolution of the 13 overall COVID-19 symptoms from 30 to 21 days. In an exploratory analysis of patients ages 45 and older or with one or more comorbidity, KB109 significantly reduced median time to resolution of the 13 overall COVID-19 symptoms from 31 to 21 days. KB109 targets the host immune system rather than the virus and is therefore likely to demonstrate similar results against emerging virus variants, though this has not yet been studied in an IND trial. As a non-interventional extension to the completed study, Kaleido is continuing to study the impact of KB109 on the incidence of 'Long-COVID'-an emerging concern where symptoms of the virus persist in patients for weeks and months. The mechanism of KB109's induction of short-chain fatty acid production is validated in multiple preclinical studies across both viral and bacterial respiratory pathogens, offering the potential to provide an intervention for a variety of viral respiratory infections.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$9.95 /

-0.96 (-8.80%)

KLDO Kaleido Biosciences
$9.95 /

-0.96 (-8.80%)

02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
KLDO Kaleido Biosciences
$9.95 /

-0.96 (-8.80%)

  • 04
    Feb
  • 02
    Jun
KLDO Kaleido Biosciences
$9.95 /

-0.96 (-8.80%)

Conference/Events
Kaleido Biosciences participates in a conference call with JMP Securities » 04:55
03/24/21
03/24
04:55
03/24/21
04:55
KLDO

Kaleido Biosciences

$9.95 /

-0.96 (-8.80%)

Conference call with…

Conference call with management will be held on March 24 hosted by JMP Securities.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$9.95 /

-0.96 (-8.80%)

KLDO Kaleido Biosciences
$9.95 /

-0.96 (-8.80%)

02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
KLDO Kaleido Biosciences
$9.95 /

-0.96 (-8.80%)

  • 04
    Feb
  • 02
    Jun
KLDO Kaleido Biosciences
$9.95 /

-0.96 (-8.80%)

Conference/Events
Kaleido Biosciences management to meet virtually with JMP Securities » 04:55
03/19/21
03/19
04:55
03/19/21
04:55
KLDO

Kaleido Biosciences

$10.45 /

+0.03 (+0.29%)

Virtual Meeting to be…

Virtual Meeting to be held on March 19 hosted by JMP Securities.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$10.45 /

+0.03 (+0.29%)

KLDO Kaleido Biosciences
$10.45 /

+0.03 (+0.29%)

02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
KLDO Kaleido Biosciences
$10.45 /

+0.03 (+0.29%)

  • 04
    Feb
  • 02
    Jun
KLDO Kaleido Biosciences
$10.45 /

+0.03 (+0.29%)

Conference/Events
Kaleido Biosciences management to meet virtually with JMP Securities » 13:54
03/17/21
03/17
13:54
03/17/21
13:54
KLDO

Kaleido Biosciences

$10.23 /

-0.02 (-0.20%)

Virtual Meeting to be…

Virtual Meeting to be held on March 19 hosted by JMP Securities.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$10.23 /

-0.02 (-0.20%)

KLDO Kaleido Biosciences
$10.23 /

-0.02 (-0.20%)

02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
KLDO Kaleido Biosciences
$10.23 /

-0.02 (-0.20%)

  • 04
    Feb
  • 02
    Jun
KLDO Kaleido Biosciences
$10.23 /

-0.02 (-0.20%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.